Publications by authors named "Alberto Chavez-Velazquez"
Objective: To examine the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) alone or with glucagon-like peptide 1 receptor agonists (GLP-1RAs) on β-cell function (BCF) in type 2 diabetes. The hypothesis was that an SGLT2i combined with a GLP-1RA provides superior improvement in BCF than either agent alone.
Research Design And Methods: Ninety patients underwent a 180-min oral glucose tolerance test (OGTT) 1) after one drug dose (acute study) (placebo [n = 15], dapagliflozin [n = 25], exenatide [n = 25], and dapagliflozin/exenatide [n = 25]) and 2) after 1 and 4 months of therapy.
Article Synopsis
- The study aimed to assess how well 1-hour plasma glucose (PG) levels during an oral glucose tolerance test (OGTT) can predict the risk of developing prediabetes in individuals with normal glucose tolerance after 7.5 years.
- Out of 1,557 participants, about 24.7% progressed to prediabetes, with higher 1-hour PG levels correlating to increased risk; specifically, those with levels above 155 mg/dL showed greater progression rates.
- The findings suggest using a cut-off point of 120 mg/dL for 1-hour PG to identify individuals at risk, coining the term "pre-prediabetes" for those who show significant insulin resistance and
Mesenteric Visceral Lipectomy Improves Glucose Tolerance in Patients With Type 2 Diabetes: A Pilot Study.
J Clin Endocrinol Metab
August 2025
Context: Increased mesenteric visceral fat is associated with the metabolic syndrome, insulin resistance, and type 2 diabetes.
Methods: Using targeted cell separation and extraction technology (TC-SET), we examined the effect of removal of intra-abdominal fat, specifically small bowel mesenteric fat, on glycemic control and insulin sensitivity in 7 individuals with obesity and poorly controlled type 2 diabetes (T2D) (glycated hemoglobin [HbA1c] = 8.9% ± 0.
The insulin-sensitizer pioglitazone exerts its cardiometabolic benefits in type 2 diabetes (T2D) through a redistribution of body fat, from ectopic and visceral areas to subcutaneous adipose depots. Whereas excessive weight gain and lipid storage in obesity promotes insulin resistance and chronic inflammation, the expansion of subcutaneous adipose by pioglitazone is associated with a reversal of these immunometabolic deficits. The precise events driving this beneficial remodeling of adipose tissue with pioglitazone remain unclear, and whether insulin-sensitizers alter the lipidomic composition of human adipose has not previously been investigated.
View Article and Find Full Text PDFDapagliflozin lowers plasma glucose concentration and improves β-cell function.
J Clin Endocrinol Metab
May 2015
Background: β-Cell dysfunction is a core defect in T2DM, and chronic, sustained hyperglycemia has been implicated in progressive β-cell failure, ie, glucotoxicity. The aim of the present study was to examine the effect of lowering the plasma glucose concentration with dapagliflozin, a glucosuric agent, on β-cell function in T2DM individuals.
Research Design And Methods: Twenty-four subjects with T2DM received dapagliflozin (n = 16) or placebo (n = 8) for 2 weeks, and a 75-g oral glucose tolerance test (OGTT) and insulin clamp were performed before and after treatment.